Managing anaplastic thyroid carcinoma

Ejigayehu G. Abate, Robert C. Smallridge

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.

Original languageEnglish (US)
Pages (from-to)793-809
Number of pages17
JournalExpert Review of Endocrinology and Metabolism
Issue number6
StatePublished - Nov 2011


  • anaplastic thyroid carcinoma
  • multimodal treatments
  • novel therapy
  • pathogenesis
  • signaling pathways
  • staging
  • targeted therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Managing anaplastic thyroid carcinoma'. Together they form a unique fingerprint.

Cite this